Vorinostat (Zolinza) in Combination With (Velcade) Versus Vorinostat Alone in Refractory or Recurrent Advanced CTCL: A Randomized Phase III Study.

Trial Profile

Vorinostat (Zolinza) in Combination With (Velcade) Versus Vorinostat Alone in Refractory or Recurrent Advanced CTCL: A Randomized Phase III Study.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2015

At a glance

  • Drugs Bortezomib (Primary) ; Vorinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 05 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top